Pharmaceutical News

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies reports third quarter 2026 results, continued momentum in CyPath Lung commercialization...

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--Kardigan announced enrollment completion in the Phase 2b KATALYST-AV trial of ataciguat in people with aortic stenosis (AS)....

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced it will host a conference call and webcast to present data from the VRDN-008 phase 1 clinical trial in healthy volunteers and development plans for its neonatal Fc receptor (FcRn) portfolio on Monday, November 9, 2026, at 8:00 a.m. ET. Conference Call and...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy for Camzyos......

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class cancer therapies, announced today that on November 2, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 206,700 shares of common stock and 103,350 restricted stock units (“RSU...

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical- stage biotechnology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it will host a virtual event on Monday, November 9 at 8:00 AM ET to discuss topline results from its Phase 2 PIK-201 trial exploring PIKTOR in advanced endometrial cancer. To register, click here. The event will feature key opinion leader and PIK-201 principal investigator David Star...

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company developing and commercializing novel therapeutics for debilitating neurodegenerative disorders, today announced that Michael McFadden, Chief Executive Officer, and Lauren D’Angelo, Chief Operating Officer, will participate in the upcoming investor events: Craig-Hallum Alpha Select Conference Format: 1x1 meetings Date: Tuesday, No...

OTTAWA, Ontario--(BUSINESS WIRE)--BIOTECanada welcomes measures in Budget 2026 that can help strengthen Canada’s life sciences sector, including expanded support for research and development, new investment incentives and additional funding for strategic sectors, including biomanufacturing. “Expanding SR&ED eligibility to include certain regulatory approval and intellectual property costs is an important step for biotechnology companies,” said Wendy Zatylny, President and CEO of BIOTECanada...

FOSTER CITY, Calif.--(BUSINESS WIRE)--New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence of Daily Oral F/TDF in HIV Prevention...

MIAMI & ORLANDO, Fla.--(BUSINESS WIRE)--The American College of Rheumatology (ACR), the professional organization representing more than 10,600 rheumatology professionals worldwide, and OpenEvidence, the most widely used medical AI platform among U.S. physicians, today announced a collaboration at ACR Convergence 2026 to make ACR’s patient education resources available within OpenEvidence, helping rheumatologists, as well as primary care physicians and other specialists managing rheumatic condi...